MarketBeat
17 Nov 2026, 01:18 UTC · 58m ago
Omeros Q3 Earnings Call Highlights
Impact · against what's priced in
OMER sees a net positive from strong US commercial momentum and new reimbursement incentives, though this is partially offset by the loss of European market access. The operational shift toward profitability and growing US account penetration provides a tangible floor despite non-cash accounting volatility.
- OMER+0.30
No priced-in read yet
- In context
Strong US growth for YARTEMLEA (26% QoQ increase to $35.9M) and a new Medicare add-on payment of up to $287k per case provide a bullish catalyst, while the negative EMA opinion removes the immediate European upside.
Read from the article alone

Search tags




